Yayın:
Determination of levetiracetam by GC-MS and effects of storage conditions and gastric digestive systems on drug samples

dc.contributor.authorErulas, Fatih Ahmet
dc.contributor.authorChormey, Dotse Selali
dc.contributor.authorOz, Ersoy
dc.contributor.authorBakirdere, Sezgin
dc.date.accessioned2026-06-27T14:45:14Z
dc.date.issued2021
dc.description.abstractBackground: Epilepsy is a neurologic condition that is occurs globally and is associated with various degrees of seizures. Levetiracetam is an approved drug that is commonly used to treat seizures in juvenile epileptic patients. Accurate quantification of the drug's active compound and determining its stability in the stomach after oral administration are important tasks that must be performed. Results & methodology: Levetiracetam was extracted from drug samples and quantified by gas chromatography mass spectrometry using calibration standards. Stability of levetiracetam was studied under various storage conditions and in simulated gastric conditions. The calibration plot determined for levetiracetam showed good linearity with a coefficient of determination value of 0.9991. The limits of detection and quantification were found to be 0.004 and 0.014 mu g center dot ml(-1), respectively. The structural integrity of levetiracetam did not change within a 4-h period under the simulated gastric conditions, and no significant degradation was observed for the different storage temperatures tested. Discussion & conclusion: An accurate and sensitive quantitative method was developed for the determination of levetiracetam in drug samples. The stability of the drug active compound was monitored under various storage and gastric conditions. The levetiracetam content determined in the drug samples were within +/- 10% of the value stated on the drug labels.en
dc.description.urihttps://doi.org/10.4155/bio-2021-0258
dc.identifier.doi10.4155/bio-2021-0258
dc.identifier.eissn1757-6199
dc.identifier.endpage222
dc.identifier.issn1757-6180
dc.identifier.issue4
dc.identifier.pubmed35014882
dc.identifier.startpage217
dc.identifier.urihttps://hdl.handle.net/20.500.14981/64341
dc.identifier.volume14
dc.identifier.wos000741059500001
dc.language.isoeng
dc.publisherNewlands Press Ltd
dc.relation.ispartofBIOANALYSIS
dc.subjectepilepsy
dc.subjectGC-MS
dc.subjectlevetiracetam
dc.subjectsimulated gastric conditions
dc.subjectCLINICAL PHARMACOKINETICS
dc.subjectANTIEPILEPTIC DRUGS
dc.subjectLC METHOD
dc.subjectPOLYTHERAPY
dc.subjectPERFORMANCE
dc.subjectZONISAMIDE
dc.subjectMANAGEMENT
dc.subjectBiochemistry & Molecular Biology
dc.subjectChemistry
dc.titleDetermination of levetiracetam by GC-MS and effects of storage conditions and gastric digestive systems on drug samples
dc.typeArticle
dspace.entity.typePublication
local.import.sourceWOS

Dosyalar

Koleksiyonlar